Policy & Regulation
Tempus expands oncology collaboration with Gilead to accelerate AI-driven R&D
9 April 2026 - Technology company Tempus AI Inc (NASDAQ:TEM) on Thursday announced an expanded multi-year collaboration with biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) to support the ...
Eli Lilly launches Foundayo weight‑loss pill in the US
...
AtaiBeckley reports rapid and durable Phase 2a responses to BPL‑003 in treatment‑resistant depression
...
Solvonis Therapeutics secures second US patent for PTSD compound series
8 April 2026 - Solvonis Therapeutics plc (LSE: SVNS), a biopharmaceutical company developing small-molecule treatments for central nervous system disorders, announced on Wednesday that it has been gra...
GSK secures China approval for Exdensur to treat nasal polyp condition
8 April 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) revealed on Wednesday that it has received approval from China's National Medical Products Administration for Exdensur (dep...
Ondine Biomedical ICU study accepted by Journal of Critical Care
8 April 2026 - Canadian life sciences company Ondine Biomedical Inc (LSE: OBI) reported on Wednesday that a pilot study evaluating its nasal photodisinfection therapy in an intensive care unit setting...